Natasha Leighl

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

C. Gridelli, G. Ceresoli, M. Piccirillo, 2023, The Lancet.

The Cost-Effectiveness of Second-Line Crizotinib in Eml4-Alk Rearranged Advanced Non-Small Cell Lung Cancer.

M. Tsao, J. Hoch, D. Graham, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.